Idiopathic Intracranial Hypertension Treatment Market Report 2026

The idiopathic intracranial hypertension treatment market size has grown strongly in recent years. It will grow from $1.48 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rising incidence of obesity-related neurological disorders, improved availability of neuroimaging techniques, increased awareness of vision-related complications, hospital-based management of severe cases, established use of acetazolamide therapy.

The idiopathic intracranial hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growing prevalence of obesity globally, advancements in minimally invasive neurosurgical techniques, expansion of specialty neurology clinics, increasing focus on early screening and diagnosis, development of novel therapeutic approaches. Major trends in the forecast period include growing use of pharmacological management as first-line therapy, increasing focus on early diagnosis to prevent vision loss, rising adoption of minimally invasive surgical interventions, expansion of multidisciplinary care models for IIH management, increasing emphasis on lifestyle and weight management programs.

The rising prevalence of obesity is expected to drive growth in the idiopathic intracranial hypertension treatment market in the coming years. Obesity is a medical condition characterized by excessive body fat that can negatively impact health. Increasingly sedentary lifestyles and higher consumption of calorie-dense processed foods are contributing to the rise in obesity. Excess body fat can elevate intracranial pressure by increasing cerebrospinal fluid production and impairing its absorption, thereby contributing to idiopathic intracranial hypertension. For example, in 2024, the Office for Health Improvement and Disparities, a UK government body, reported that between 2022 and 2023, 64% of adults aged 18 and over in England were classified as overweight or living with obesity. Consequently, the growing prevalence of obesity is driving demand for IIH treatments.

Key companies in the idiopathic intracranial hypertension treatment market are focusing on developing novel, fast-acting therapies capable of safely reducing brain pressure and improving headache outcomes. For instance, in March 2023, researchers at the University of Birmingham (UK) reported promising phase two results for exenatide, an injectable GLP-1 receptor agonist currently used for type 2 diabetes, as a potential IIH treatment. The study demonstrated that patients receiving exenatide experienced a rapid and significant reduction in brain pressure, with sustained improvements over 12 weeks. Participants also reported nearly eight fewer headache days per month compared with minimal changes in the placebo group. As IIH incidence rises alongside global obesity, this evidence highlights the potential for a much-needed licensed therapy for a condition that can cause severe headaches and vision loss.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for $12 billion. This acquisition enhances BMS’s neuroscience portfolio by adding KarXT, a novel antipsychotic with a unique mechanism of action and a promising safety and efficacy profile. The acquisition supports BMS’s long-term growth strategy and strengthens its ability to address critical unmet needs in neurodegenerative and neurological conditions. Karuna Therapeutics Inc. is a US-based biopharmaceutical company specializing in therapies for neurological disorders.

Major companies operating in the idiopathic intracranial hypertension treatment market are Siemens AG, Medtronic plc, Becton Dickinson and Company, Philips Healthcare, GE HealthCare Technologies Inc., Teva Pharmaceuticals, Boston Scientific Corporation, Henry Schein, Sun Pharmaceutical Industries, Zydus LifeSciences, Topcon Corporation, Natus Medical Incorporated, Canon Medical Systems Corporation, Carl Zeiss Meditec AG, Optopol Technology, Strides Pharma, NIDEK Co., Haag-Streit AG, Invex Therapeutics, Metrovision.

North America was the largest region in the idiopathic intracranial hypertension treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic intracranial hypertension treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idiopathic intracranial hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the idiopathic intracranial hypertension treatment market by increasing costs for imported neuroimaging equipment, surgical devices, and specialized medical consumables used in diagnosis and intervention. These impacts are more pronounced in regions dependent on imported healthcare technologies, including parts of Asia-Pacific and Latin America. However, tariffs are also encouraging local manufacturing of medical devices, diversification of suppliers, and cost-optimization strategies that may support long-term market growth and accessibility.

The idiopathic intracranial hypertension treatment market research report is one of a series of new reports that provides idiopathic intracranial hypertension treatment market statistics, including idiopathic intracranial hypertension treatment industry global market size, regional shares, competitors with a idiopathic intracranial hypertension treatment market share, detailed idiopathic intracranial hypertension treatment market segments, market trends and opportunities, and any further data you may need to thrive in the idiopathic intracranial hypertension treatment industry. This idiopathic intracranial hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Idiopathic intracranial hypertension (IIH) treatment encompasses medical and surgical approaches aimed at reducing intracranial pressure and preventing complications such as vision loss. These treatments may include lifestyle modifications, such as weight loss, medications like acetazolamide to reduce cerebrospinal fluid accumulation, and surgical interventions, including shunt placement or optic nerve sheath fenestration for severe cases.

The main types of IIH treatment include medications, surgeries, and supportive therapies. Medications are used to lower cerebrospinal fluid production, relieve symptoms such as headaches and vision disturbances, and address underlying contributing conditions. These medications can be administered orally or via intrathecal delivery. Diagnostic methods include neuroimaging, lumbar puncture, and visual field assessments, and treatments are typically provided in hospitals, specialized clinics, or ambulatory surgical centers.

The idiopathic intracranial hypertension treatment market consists of revenues earned by entities by providing services such as diagnostic imaging services, nutritional counseling, optic nerve sheath fenestration procedures, ophthalmologic evaluations, and visual field monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The idiopathic intracranial hypertension treatment market also includes sales of shunt systems, surgical instruments, intracranial pressure monitoring devices, and optical coherence tomography (OCT). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.